PUNIT DHILLON - 06 Feb 2026 Form 4 Insider Report for Skye Bioscience, Inc. (SKYE)

Role
Chief Executive Officer, Director
Signature
/s/ Kaitlyn Arsenault, as Attorney-in-Fact
Issuer symbol
SKYE
Transactions as of
06 Feb 2026
Net transactions value
$0
Form type
4
Filing time
09 Feb 2026, 20:54:11 UTC
Previous filing
26 Feb 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
DHILLON PUNIT Chief Executive Officer, Director 11250 EL CAMINO REAL, SUITE 100, C/O SKYE BIOSCIENCE, INC., SAN DIEGO /s/ Kaitlyn Arsenault, as Attorney-in-Fact 09 Feb 2026 0001425052

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SKYE Stock Option (Right to Buy) Award $0 +280,000 $0.000000 280,000 06 Feb 2026 Common Stock 280,000 $0.8200 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests in equal monthly installments over the four-year period beginning January 19, 2026.